165 related articles for article (PubMed ID: 18790646)
1. RCAI-17, 22, 24-26, 29, 31, 34-36, 38-40, and 88, the analogs of KRN7000 with a sulfonamide linkage: their synthesis and bioactivity for mouse natural killer T cells to produce Th2-biased cytokines.
Tashiro T; Hongo N; Nakagawa R; Seino K; Watarai H; Ishii Y; Taniguchi M; Mori K
Bioorg Med Chem; 2008 Oct; 16(19):8896-906. PubMed ID: 18790646
[TBL] [Abstract][Full Text] [Related]
2. RCAI-61 and related 6'-modified analogs of KRN7000: their synthesis and bioactivity for mouse lymphocytes to produce interferon-γ in vivo.
Tashiro T; Nakagawa R; Shigeura T; Watarai H; Taniguchi M; Mori K
Bioorg Med Chem; 2013 Jun; 21(11):3066-79. PubMed ID: 23602521
[TBL] [Abstract][Full Text] [Related]
3. RCAI-37, 56, 59, 60, 92, 101, and 102, cyclitol and carbasugar analogs of KRN7000: their synthesis and bioactivity for mouse lymphocytes to produce Th1-biased cytokines.
Tashiro T; Nakagawa R; Hirokawa T; Inoue S; Watarai H; Taniguchi M; Mori K
Bioorg Med Chem; 2009 Sep; 17(17):6360-73. PubMed ID: 19656685
[TBL] [Abstract][Full Text] [Related]
4. RCAI-8, 9, 18, 19, and 49-52, conformationally restricted analogues of KRN7000 with an azetidine or a pyrrolidine ring: Their synthesis and bioactivity for mouse natural killer T cells to produce cytokines.
Fuhshuku K; Hongo N; Tashiro T; Masuda Y; Nakagawa R; Seino K; Taniguchi M; Mori K
Bioorg Med Chem; 2008 Jan; 16(2):950-64. PubMed ID: 17950609
[TBL] [Abstract][Full Text] [Related]
5. RCAI-84, 91, and 105-108, ureido and thioureido analogs of KRN7000: their synthesis and bioactivity for mouse lymphocytes to produce Th1-biased cytokines.
Tashiro T; Shigeura T; Watarai H; Taniguchi M; Mori K
Bioorg Med Chem; 2012 Jul; 20(14):4540-8. PubMed ID: 22739091
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of RCAI-172 (C6 epimer of RCAI-147) and its biological activity.
Shiozaki M; Tashiro T; Koshino H; Shigeura T; Watarai H; Taniguchi M; Mori K
Bioorg Med Chem; 2014 Jan; 22(2):827-33. PubMed ID: 24360828
[TBL] [Abstract][Full Text] [Related]
7. Pivotal advance: alpha-galactosylceramide induces protection against lipopolysaccharide-induced shock.
Sireci G; La Manna MP; Di Sano C; Di Liberto D; Porcelli SA; Kronenberg M; Dieli F; Salerno A
J Leukoc Biol; 2007 Mar; 81(3):607-22. PubMed ID: 17046969
[TBL] [Abstract][Full Text] [Related]
8. Focus on the controversial activation of human iNKT cells by 4-deoxy analogue of KRN7000.
Lacône V; Hunault J; Pipelier M; Blot V; Lecourt T; Rocher J; Turcot-Dubois AL; Marionneau S; Douillard JY; Clément M; Le Pendu J; Bonneville M; Micouin L; Dubreuil D
J Med Chem; 2009 Aug; 52(15):4960-3. PubMed ID: 19580320
[TBL] [Abstract][Full Text] [Related]
9. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide.
Chiba A; Oki S; Miyamoto K; Hashimoto H; Yamamura T; Miyake S
Arthritis Rheum; 2004 Jan; 50(1):305-13. PubMed ID: 14730629
[TBL] [Abstract][Full Text] [Related]
10. Cytokine production and migration of in vitro-expanded NK1.1(-) invariant Valpha14 natural killer T (Valpha14i NKT) cells using alpha-galactosylceramide and IL-2.
Ikarashi Y; Iizuka A; Heike Y; Yoshida M; Takaue Y; Wakasugi H
Immunol Lett; 2005 Nov; 101(2):160-7. PubMed ID: 16054231
[TBL] [Abstract][Full Text] [Related]
11. Enhancing effects of (2S,3S,4R)-1-O-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino) -1,3,4-octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells.
Yamaguchi Y; Motoki K; Ueno H; Maeda K; Kobayashi E; Inoue H; Fukushima H; Koezuka Y
Oncol Res; 1996; 8(10-11):399-407. PubMed ID: 9114432
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver.
Fuji N; Ueda Y; Fujiwara H; Toh T; Yoshimura T; Yamagishi H
Clin Cancer Res; 2000 Aug; 6(8):3380-7. PubMed ID: 10955826
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological activity of hydroxylated analogues of KRN7000 (α-galactosylceramide).
Shiozaki M; Tashiro T; Koshino H; Shigeura T; Watarai H; Taniguchi M; Mori K
Carbohydr Res; 2013 Apr; 370():46-66. PubMed ID: 23454137
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of 1,2,3-triazole containing analogues of the immunostimulant alpha-GalCer.
Lee T; Cho M; Ko SY; Youn HJ; Baek DJ; Cho WJ; Kang CY; Kim S
J Med Chem; 2007 Feb; 50(3):585-9. PubMed ID: 17266209
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production.
Nakagawa R; Motoki K; Nakamura H; Ueno H; Iijima R; Yamauchi A; Tsuyuki S; Inamoto T; Koezuka Y
Oncol Res; 1998; 10(11-12):561-8. PubMed ID: 10367937
[TBL] [Abstract][Full Text] [Related]
16. A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells.
Liu Y; Goff RD; Zhou D; Mattner J; Sullivan BA; Khurana A; Cantu C; Ravkov EV; Ibegbu CC; Altman JD; Teyton L; Bendelac A; Savage PB
J Immunol Methods; 2006 May; 312(1-2):34-9. PubMed ID: 16647712
[TBL] [Abstract][Full Text] [Related]
17. 3-fluoro- and 3,3-difluoro-3,4-dideoxy-KRN7000 analogues as new potent immunostimulator agents: total synthesis and biological evaluation in human invariant natural killer T cells and mice.
Hunault J; Diswall M; Frison JC; Blot V; Rocher J; Marionneau-Lambot S; Oullier T; Douillard JY; Guillarme S; Saluzzo C; Dujardin G; Jacquemin D; Graton J; Le Questel JY; Evain M; Lebreton J; Dubreuil D; Le Pendu J; Pipelier M
J Med Chem; 2012 Feb; 55(3):1227-41. PubMed ID: 22243602
[TBL] [Abstract][Full Text] [Related]
18. KRN7000, a novel immunomodulator, and its antitumor activities.
Kobayashi E; Motoki K; Uchida T; Fukushima H; Koezuka Y
Oncol Res; 1995; 7(10-11):529-34. PubMed ID: 8866665
[TBL] [Abstract][Full Text] [Related]
19. The synthesis and in vivo evaluation of 2',2'-difluoro KRN7000.
Leung L; Tomassi C; Van Beneden K; Decruy T; Trappeniers M; Elewaut D; Gao Y; Elliott T; Al-Shamkhani A; Ottensmeier C; Werner JM; Williams A; Van Calenbergh S; Linclau B
ChemMedChem; 2009 Mar; 4(3):329-34. PubMed ID: 19137519
[TBL] [Abstract][Full Text] [Related]
20. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production.
Bourgeois E; Van LP; Samson M; Diem S; Barra A; Roga S; Gombert JM; Schneider E; Dy M; Gourdy P; Girard JP; Herbelin A
Eur J Immunol; 2009 Apr; 39(4):1046-55. PubMed ID: 19266498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
